Progenics Pharmaceuticals to Present at Upcoming Investor Conferences
November 06 2018 - 8:00AM
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), an oncology company
developing innovative medicines and imaging analysis technology for
targeting and treating cancer, today announced that management will
present at the following upcoming investor conferences in November:
- Credit Suisse 27th Annual Healthcare Conference in Scottsdale,
AZ, on Tuesday, November 13, 2018, at 9:10 a.m. PT.
- Stifel 2018 Healthcare Conference in New York, NY on Wednesday,
November 14, 2018 at 2:00 p.m. ET.
- Jefferies 2018 London Healthcare Conference in London, UK on
Thursday, November 15, 2018 at 8:00 a.m. GMT.
A live webcast of each presentation will be
available in the Media Center of the Progenics website,
www.progenics.com. To ensure a timely connection, users should
register at least 15 minutes prior to the scheduled start. An
archive of the event will be available for 90 days.
About ProgenicsProgenics
develops innovative medicines and other technologies to target and
treat cancer, including: 1) therapeutic agents designed to treat
cancer (AZEDRA®, PSMA TTC and 1095), 2) PSMA-targeted imaging
agents for prostate cancer (1404 and PyL™), and 3) imaging analysis
technology (PSMA AI and aBSI). Progenics has two commercial
products, AZEDRA, for the treatment of unresectable, locally
advanced or metastatic pheochromocytoma or paraganglioma (rare
neuroendocrine tumors of neural crest origin) who require systemic
anticancer therapy; and RELISTOR® (methylnaltrexone bromide)
for opioid-induced constipation, which is partnered
with Bausch Health Companies, Inc
This press release contains projections and
other "forward-looking statements" regarding future events.
Statements contained in this communication that refer to Progenics'
estimated or anticipated future results or other non-historical
facts are forward-looking statements that reflect Progenics'
current perspective of existing trends and information as of the
date of this communication. Forward looking statements generally
will be accompanied by words such as "anticipate," "believe,"
"plan," "could," "should," "estimate," "expect," "forecast,"
"outlook," "guidance," "intend," "may," "might," "will,"
"possible," "potential," "predict," "project," or other similar
words, phrases or expressions. Such statements are predictions
only, and are subject to risks and uncertainties that could cause
actual events or results to differ materially. These risks and
uncertainties include, among others, market acceptance for approved
products; the risk that the planned commercial launch of AZEDRA may
not meet revenue and income expectations; the cost, timing and
unpredictability of results of clinical trials and other
development activities and collaborations; the unpredictability of
the duration and results of regulatory review of New Drug
Applications (NDA) and Investigational NDAs; possible product
safety or efficacy concerns, general business, financial,
regulatory and accounting matters, litigation and other risks. More
information concerning Progenics and such risks and uncertainties
is available on its website, and in its press releases and reports
it files with the U.S. Securities and Exchange Commission,
including those risk factors included in its Annual Report on Form
10-K for the annual period ended December 31, 2017, as updated in
its subsequent Quarterly Reports on Form 10-Q. Progenics is
providing the information in this press release as of its date and,
except as expressly required by law, Progenics disclaims any intent
or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
circumstances or otherwise.
Additional information concerning Progenics and
its business may be available in press releases or other public
announcements and public filings made after this release. For more
information, please visit www.progenics.com. Information on or
accessed through our website or social media sites is not included
in the company's SEC filings.
(PGNX-F)
Contact: |
Melissa Downs |
|
Investor Relations |
|
(646)
975-2533 |
|
mdowns@progenics.com |
Progenics Pharmaceuticals (NASDAQ:PGNX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Progenics Pharmaceuticals (NASDAQ:PGNX)
Historical Stock Chart
From Sep 2023 to Sep 2024